Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership

 
• By Joseph Haas

Deal snapshot: Ovid expects to report Phase III data for its Angelman syndrome drug during Q4 2020. It calls Angelini an ideal European partner; deal leaves Ovid to focus its efforts and resources on the US.

businessman and businesswoman are exchanging document or contract
Ovid/Angelini partnership is the first deal for an Angelman syndrome therapy

More from Deals

More from Business